Received Mar 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
red painful lump on their arm; red painful lump; painful lump; chilled; couldn't function for the rest of the day; This non-serious case was reported by a consumer and described the occurrence of erythema in a patient who received Herpes zoster (Shingrix) for prophylaxis. On 05-FEB-2025, the patient received Shingrix. On 05-FEB-2025, 4 hrs after receiving Shingrix, the patient experienced activities of daily living impaired (Verbatim: couldn't function for the rest of the day). On 06-FEB-2025, the patient experienced erythema (Verbatim: red painful lump on their arm), local swelling (Verbatim: red painful lump), pain (Verbatim: painful lump) and chills (Verbatim: chilled). The outcome of the erythema, local swelling, pain and activities of daily living impaired were not resolved and the outcome of the chills was not reported. It was unknown if the reporter considered the erythema, local swelling, pain, chills and activities of daily living impaired to be related to Shingrix. It was unknown if the company considered the erythema, local swelling, pain, chills and activities of daily living impaired to be related to Shingrix. Additional Information: GSK Receipt Date: 07-FEB-2025 The patient received the Shingrix vaccine and after 4 hours, could not function for the rest of the day. The patient had a chilled, red painful lump on their arm.